Presentation is loading. Please wait.

Presentation is loading. Please wait.

Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.

Published bySophia Stanley Modified over 8 years ago

Similar presentations

Presentation on theme: "Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive."— Presentation transcript:

1 Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline Ann Intern Med. 2012;156(8):570-581. doi:10.7326/0003-4819-156-8-201204170-00008 Definition of CKD. CKD = chronic kidney disease; GFR = glomerular filtration rate. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

2 Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline Ann Intern Med. 2012;156(8):570-581. doi:10.7326/0003-4819-156-8-201204170-00008 Analytic framework. The patient population of interest is asymptomatic adults with or without CKD risk factors. The first and second key questions are related to benefits (KQ1) and harms (KQ2) of screening this population for the presence of CKD stages 1 to 3. The third and fourth key questions are related to benefits (KQ3) and harms (KQ4) associated with monitoring patients with early CKD. The fifth and sixth key questions are related to benefits (KQ5) and harms (KQ6) associated with treatment of patients with early CKD. The framework shows that monitoring may lead to treatment and that treatment may be monitored. The framework also includes intermediate outcomes of treatment that may be associated with the clinical outcomes of interest. ACEI = angiotensin-converting enzyme inhibitor; AKI = acute kidney injury; ARB = angiotensin II–receptor blocker; CHF = congestive heart failure; CKD = chronic kidney disease; CVA = cerebrovascular accident; CVD = cardiovascular disease; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; ESRD = end-stage renal disease; HTN = hypertension; KQ = key question; MI = myocardial infarction; QOL = quality of life. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

3 Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline Ann Intern Med. 2012;156(8):570-581. doi:10.7326/0003-4819-156-8-201204170-00008 Summary of evidence search and selection. CKD = chronic kidney disease; RCT = randomized, controlled trial. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Download ppt "Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive."

Similar presentations

The National Kidney Foundations Kidney Early Evaluation Program TM The National Kidney Foundations Kidney Early Evaluation Program TM Essex-Passaic Wellness.

The National Kidney Foundations Kidney Early Evaluation Program TM The National Kidney Foundations Kidney Early Evaluation Program TM Essex-Passaic Wellness.
Diabetes, Anemia and Chronic Kidney Disease Josephine Carlos-Raboca,M.D., F.P.S.E.M., Endocrinology, Diabetes and Metabolism Makati Medical Center.

Diabetes, Anemia and Chronic Kidney Disease Josephine Carlos-Raboca,M.D., F.P.S.E.M., Endocrinology, Diabetes and Metabolism Makati Medical Center.
Chapter 2: Identification and Care of Patients With CKD 2014 ANNUAL DATA REPORT VOLUME 1: CHRONIC KIDNEY DISEASE.

Chapter 2: Identification and Care of Patients With CKD 2014 ANNUAL DATA REPORT VOLUME 1: CHRONIC KIDNEY DISEASE.
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
Stages of CKD – KDOQI 2002 Definitions

Stages of CKD – KDOQI 2002 Definitions
Management of Chronic Kidney Disease Stages 1 – 3 Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov.

Management of Chronic Kidney Disease Stages 1 – 3 Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Definitions and classification of office blood pressure levels (mmHg) Modified by ESC Guidelines 2013 CARDIOcheckAPP.

Definitions and classification of office blood pressure levels (mmHg) Modified by ESC Guidelines 2013 CARDIOcheckAPP.
Date of download: 5/28/2016 From: New Fibrate Use and Acute Renal Outcomes in Elderly Adults: A Population-Based Study Ann Intern Med. 2012;156(8):560-569.

Date of download: 5/28/2016 From: New Fibrate Use and Acute Renal Outcomes in Elderly Adults: A Population-Based Study Ann Intern Med. 2012;156(8):
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.
Date of download: 5/28/2016 From: Primary Care–Relevant Interventions to Prevent Falling in Older Adults: A Systematic Evidence Review for the U.S. Preventive.

Date of download: 5/28/2016 From: Primary Care–Relevant Interventions to Prevent Falling in Older Adults: A Systematic Evidence Review for the U.S. Preventive.
Date of download: 5/28/2016 From: Optimal Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Review.

Date of download: 5/28/2016 From: Optimal Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Review.
Date of download: 6/2/2016 From: Screening for Vitamin D Deficiency: A Systematic Review for the U.S. Preventive Services Task Force Ann Intern Med. 2015;162(2):109-122.

Date of download: 6/2/2016 From: Screening for Vitamin D Deficiency: A Systematic Review for the U.S. Preventive Services Task Force Ann Intern Med. 2015;162(2):
Date of download: 6/3/2016 From: Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial.

Date of download: 6/3/2016 From: Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial.
Date of download: 6/3/2016 From: Elevated Plasma Homocysteine Level Is an Independent Predictor of Coronary Heart Disease Events in Patients with Type.

Date of download: 6/3/2016 From: Elevated Plasma Homocysteine Level Is an Independent Predictor of Coronary Heart Disease Events in Patients with Type.
Date of download: 6/3/2016 From: The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease:

Date of download: 6/3/2016 From: The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease:
Date of download: 6/6/2016 From: Comparative Effectiveness of Pain Management Interventions for Hip Fracture: A Systematic Review Ann Intern Med. 2011;155(4):234-245.

Date of download: 6/6/2016 From: Comparative Effectiveness of Pain Management Interventions for Hip Fracture: A Systematic Review Ann Intern Med. 2011;155(4):
Date of download: 6/18/2016 From: Treatment of Anemia in Patients With Heart Disease: A Systematic Review Ann Intern Med. 2013;159(11):746-757. doi:10.7326/0003-4819-159-11-201312030-00007.

Date of download: 6/18/2016 From: Treatment of Anemia in Patients With Heart Disease: A Systematic Review Ann Intern Med. 2013;159(11): doi: /
Date of download: 6/21/2016 From: Low-Dose Aspirin for Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the U.S.

Date of download: 6/21/2016 From: Low-Dose Aspirin for Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the U.S.
Date of download: 6/21/2016 From: Psychological and Behavioral Interventions for Managing Insomnia Disorder: An Evidence Report for a Clinical Practice.

Date of download: 6/21/2016 From: Psychological and Behavioral Interventions for Managing Insomnia Disorder: An Evidence Report for a Clinical Practice.
Date of download: 6/21/2016 From: Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services.

Date of download: 6/21/2016 From: Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services.

Similar presentations

Ads by Google